Posted by Michael Wonder on 27 Aug 2025
Cereno Scientific granted FDA fast track designation for CS1 in rare disease pulmonary arterial hypertension
26 August 2025 - Cereno Scientific today announced that the US FDA has granted fast track designation to its lead program, CS1, for the treatment of pulmonary arterial hypertension.
Drug candidate CS1 is an oral HDAC inhibitor with a unique mechanism of action through epigenetic modulation.
